SCHEDULE: Bellevue Group Discloses 5.6% Stake in Immunocore

Bellevue Group AG and its subsidiary Bellevue Asset Management AG have reported a 5.6% beneficial ownership stake in Immunocore Holdings plc.

Summary

• Bellevue Group AG and its wholly-owned subsidiary, Bellevue Asset Management AG, have disclosed beneficial ownership of 2,796,803 ordinary shares of Immunocore Holdings plc.
• This stake represents 5.6% of Immunocore's ordinary shares outstanding, calculated based on 50,233,609 shares.
• The reporting entities, both based in Switzerland, hold shared voting and dispositive power over all 2,796,803 shares.
• The filing indicates the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant institutional stake by a reputable asset manager is generally viewed positively, indicating confidence in the company's prospects. However, the filing itself provides no operational or financial updates from the company.

Positives

• Disclosure of a significant institutional stake (5.6%) by Bellevue Group AG and Bellevue Asset Management AG may signal confidence in Immunocore Holdings plc's future prospects.
• The acquisition of shares in the ordinary course of business suggests a long-term investment perspective rather than an activist stance.

Negatives

• The filing itself does not contain any explicit negative information regarding Immunocore Holdings plc.

Risks

• The filing does not mention specific risks related to Immunocore Holdings plc.

Future Outlook

Not applicable as this filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer.

Industry Context

The disclosure of a significant institutional stake by a Swiss asset manager in a biotechnology company like Immunocore Holdings plc can be viewed as a positive signal within the highly capital-intensive and research-driven pharmaceutical and biotechnology industry. Such investments often reflect a belief in the company's drug pipeline, market potential, or strategic direction, potentially attracting further investor interest.

Comparison to Industry Standards

• A 5.6% stake is a notable position for an institutional investor, indicating a significant commitment.
• While direct comparisons to specific companies or projects are not provided in this filing, institutional ownership of this magnitude is common for established biotech firms and can be seen as a vote of confidence, especially from a specialized asset manager like Bellevue Asset Management AG, which focuses on healthcare investments.

Stakeholder Impact

• Shareholders: May view the significant institutional investment as a positive indicator of confidence, potentially leading to increased investor interest and stability in the share price.
• Management: Could see this as validation of their strategy and operations, potentially influencing future engagement with the institutional investor.

Key Dates

Keywords

Immunocore Holdings plc, Bellevue Group AG, Bellevue Asset Management AG, Schedule 13G, Beneficial Ownership, Ordinary Shares, Institutional Investor, Biotechnology, Pharmaceuticals, Equity Stake